Oral hymecromone for primary sclerosing cholangitis
Part of Digestive system clinical trials.
This trial tests whether taking hymecromone by mouth can improve primary sclerosing cholangitis (a liver/bile duct condition). It may help by targeting inflammation and bile duct problems, especially in people who are stable on other medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary sclerosing cholangitis confirmed by biopsy and/or scans
- If you also have inflammatory bowel disease, it must be stable for at least 6 months
- Your inflammatory blood/stool tests must be normal (ESR, CRP, and fecal calprotectin)
- You are not currently taking biologic medicines
- You are not allergic to hymecromone
- You do not have cholangiocarcinoma (bile duct cancer) and you are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study looks at how a statin (cholesterol-lowering medicine) affects people with primary sclerosing cholangitis (PSC) by measuring changes using multiple types of health data. It may help researchers understand which people benefit and how PSC biology changes with treatment.
This study tests whether a treatment made from mouth bacteria can help people with primary sclerosing cholangitis (PSC). It aims to see if it's safe and improves health.
This study tests a new medication called elafibranor for adults with primary sclerosing cholangitis (PSC), a chronic liver disease. It aims to see if elafibranor can safely help improve liver health when compared to no treatment.
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
This Phase 2 study tests whether the antibiotic vancomycin can improve primary sclerosing cholangitis (PSC), a long-term bile-duct disease. You may be eligible if you have confirmed PSC and certain blood test and safety criteria, and you can follow medication washout rules.
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
Hear when a new Primary Sclerosing Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.